君实生物(01877)宣布JS207联合JS007一线治疗晚期肝细胞癌III期临床试验完成首例给药

公告速递
Oct 29

上海君实生物医药科技股份有限公司(01877)10月29日发布自愿性公告称,公司自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207联合重组人源化抗CTLA-4单克隆抗体JS007,用于一线治疗晚期肝细胞癌(HCC)的多中心、随机、对照、开放的III期临床研究(JS207-017-III-HCC,注册号:NCT07823348)已于近日完成首例患者给药。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10